To further determine whether the enhanced sensitivity to gemcitabine after Bmi1 inhibition is correlated with the changes of NF-κB activity in pancreatic cancer cells, we compared the status of NF-κB in pancreatic cancer cells through EMSA. Here, BMI1 is linked to pancreatic neoplasm.